Results 71 to 80 of about 8,661 (182)

Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study

BMC Infectious Diseases
Background and aim Two oral antivirals (Nirmatrelvir- ritonavir and Azvudine) are widely used in China practice during the Omicron wave of the pandemic.
Xiaobo Han, Darui Gao, Chenglong Li, Xin Yuan, Junchang Cui, Weiguo Zhao, Fei Xie, Kaifei Wang, Yuhong Liu, Guoxin Muo, Na Xi, Mengli Zheng, Rentao Wang, Kun Xiao, Dahui Zhao, Xinxin Zhang, Xinjie Han, Bo Wang, Tiantian Zhang, Wuxiang Xie, Lixin Xie   +20 more
doaj   +1 more source

Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study

Infectious Diseases and Therapy, 2023
Introduction Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19 in China due to their earlier approval by the National Medical Products Administration.
Qinqin Zhao, Bei Zheng, Bing Han, Pinpin Feng, Zhongni Xia, Hong Jiang, Yin Ying, Jun Zhu, Cheng Fei, Junlei Xiang, Lingli Shen, Qiliang Luo, Yinhuan Wu, Ayiguzhali Wusiman, Chuanwei Xin, Meiling Zhang, Gonghua Li, Xiang Li   +17 more
doaj   +1 more source

Incidence of severe COVID‐19 in patients with chronic lymphocytic leukaemia or indolent B‐cell non‐Hodgkin lymphoma who received vaccination and pre‐exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi

British Journal of Haematology, EarlyView.
Gian Matteo Rigolin, Stefano Soddu, Riccardo Dondolin, Anna Maria Frustaci, Ilaria Scortechini, Francesca Romana Mauro, Francesco Angotzi, Marina Motta, Lydia Scarfò, Andrea Mengarelli, Annamaria Giordano, Sara Martinelli, Caterina Patti, Paolo Sportoletti, Alessandro Sanna, Nilla Maschio, Rossella Riccioni, Clara Virginia Viganò, Agostino Tafuri, Alfonso Piciocchi, Paola Fazi, Stefano Luminari, Andrés J. M. Ferreri, Guido Gini, Paolo Ghia, Antonio Cuneo   +25 more
wiley   +1 more source

Enhancing the Outcome of Crystallographic Fragment Screening by Choosing the Optimal Protein Crystal Form

Small Science, Volume 6, Issue 3, March 2026.
The selection of the crystal form impacts crystallographic fragment screening (CFS) hit rates. Almost identical CFS campaigns using monoclinic versus orthorhombic crystals of SARS‐CoV‐2 main protease yield hit rates of 3% and 16%. The higher hit rate correlates with larger solvent channels and a less constrained active site in the orthorhombic form ...
Tatjana Barthel, Jan Wollenhaupt, Laila S. Benz, Patrick Reinke, Linlin Zhang, Melanie Oelker, Frank Lennartz, Helena Taberman, Uwe Mueller, Alke Meents, Rolf Hilgenfeld, Manfred S. Weiss   +11 more
wiley   +1 more source

Fixing the Achilles Heel of Pfizer’s Paxlovid for COVID-19 Treatment [PDF]

Nirmatrelvir (PF-07321332), a first-in-class inhibitor of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) main protease (Mpro), was developed by Pfizer under intense pressure during the pandemic to treat COVID-19.
Brewitz, Lennart, Schofield, Christopher J.   +1 more
core   +2 more sources

Emerging small-molecule antiviral agents in long COVID prevention

Frontiers in Pharmacology
Long COVID, or Post-Acute Sequelae of COVID-19 (PASC), was characterized by persistent symptoms such as fatigue, shortness of breath, and cognitive impairments.
Xiaomeng He, Xiang Zhang, Wu Zhong
doaj   +1 more source

Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID): protocol for a randomised controlled adaptive platform trial of treatments for acute SARS-CoV-2 infection in community settings [PDF]

Introduction: SARS-CoV-2 is now endemic and expected to remain a health threat, with new variants continuing to emerge and the potential for vaccines to become less effective.
Andrew, Melissa, Aubrey-Bassler, Kris, Barber, David, Barrett, Brendan, Butler, Christopher C, Condon, Amanda, Crampton, Noah, da Costa, Bruno R., Dahrouge, Simone, Daley, Peter, Damji, Ali, Fowler, Robert, Garies, Stephanie, Greiver, Michelle, Hosseini, Banafshe, Hudon, Catherine, Hulme, Jennifer, Isenor, Jennifer, Jüni, Peter, Lee, Todd C, McBrien, Kerry, McDonald, Emily G, Murthy, Srinivas, Selby, Peter   +23 more
core   +2 more sources

Symptoms Associated With Detection of Viral Versus Bacterial Pathogens in Outpatients With Lower Respiratory Infections

Influenza and Other Respiratory Viruses, Volume 20, Issue 3, March 2026.
ABSTRACT Purpose This study aims to identify symptoms that predict a high likelihood of viral infection, so these patients could be triaged for home care to avoid antibiotics. Methods We recruited adults presenting to US primary or urgent care sites with a chief complaint of cough and symptoms consistent with LRTI. Data collected included demographics,
Mark Ebell, Dan J. Merenstein, Bruce Barrett, Cassie Hulme, Sarah Walters, Caroline Hamer, Michelle Buhr   +6 more
wiley   +1 more source

Proportion of Patients in the United States Who Fill Their Nirmatrelvir/Ritonavir Prescriptions

Infectious Diseases and Therapy
Introduction Although real-world studies demonstrate that those prescribed nirmatrelvir/ritonavir (and particularly within 5 days of symptom onset) are less likely to experience severe COVID-19 outcomes, prior studies show that only a small fraction of ...
Abby E. Rudolph, Farid L. Khan, Tanya G. Singh, Srinivas Rao Valluri, Laura A. Puzniak, John M. McLaughlin   +5 more
doaj   +1 more source

Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study

Annals of Medicine
Background Immunocompromised patients are at high risk of developing persisting/prolonged COVID-19. Data on the early combined use of antivirals and monoclonal antibodies in this population are scarce.Research design and methods We performed an ...
I. Gentile, G. Viceconte, F. Cuccurullo, D. Pietroluongo, A. D’Agostino, M. Silvitelli, S. Mercinelli, R. Scotto, F. Grimaldi, S. Palmieri, A. Gravetti, F. Trastulli, M. Moccia, A. R. Buonomo   +13 more
doaj   +1 more source